Marksans Pharma Limited (IN:MARKSANS)
:MARKSANS
Want to see IN:MARKSANS full AI Analyst Report?
Total Valuation
Marksans Pharma Limited has a market cap or net worth of ₹113.13B. The enterprise value is ₹105.10B.
Market Cap₹113.13B
Enterprise Value₹105.10B
Share Statistics
Marksans Pharma Limited has 453,163,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding453,163,760
Owned by Insiders―
Owned by Institutions0.13%
Financial Efficiency
Marksans Pharma Limited’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 11.10%.
Return on Equity (ROE)0.14
Return on Assets (ROA)0.11
Return on Invested Capital (ROIC)11.10%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee25.86M
Profits Per Employee3.66M
Employee Count1,141
Asset Turnover0.76
Inventory Turnover1.85
Valuation Ratios
The current PE Ratio of Marksans Pharma Limited is 27.4. Marksans Pharma Limited’s PEG ratio is 1.74.
PE Ratio27.4
PS Ratio2.41
PB Ratio2.35
Price to Fair Value2.35
Price to FCF20.26
Price to Operating Cash Flow152.05
PEG Ratio1.74
Income Statement
In the last 12 months, Marksans Pharma Limited had revenue of 29.51B and earned 4.18B in profits. Earnings per share was 9.22.
Revenue29.51B
Gross Profit11.57B
Operating Income5.05B
Pretax Income5.61B
Net Income4.18B
EBITDA6.03B
Earnings Per Share (EPS)9.22
Cash Flow
In the last 12 months, operating cash flow was 751.86M and capital expenditures -731.89M, giving a free cash flow of 19.97M billion.
Operating Cash Flow751.86M
Free Cash Flow19.97M
Free Cash Flow per Share0.04
Dividends & Yields
Marksans Pharma Limited pays an annual dividend of ₹0.8, resulting in a dividend yield of 0.44%
Dividend Per Share₹0.8
Dividend Yield0.44%
Payout Ratio10.06%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.36
52-Week Price Change-2.36%
50-Day Moving Average202.32
200-Day Moving Average183.94
Relative Strength Index (RSI)66.00
Average Volume (3m)99.03K
Important Dates
Marksans Pharma Limited upcoming earnings date is Aug 7, 2026, TBA (Confirmed).
Last Earnings DateMay 26, 2026
Next Earnings DateAug 7, 2026
Ex-Dividend Date―
Financial Position
Marksans Pharma Limited as a current ratio of 5.17, with Debt / Equity ratio of 11.36%
Current Ratio5.17
Quick Ratio3.32
Debt to Market Cap0.01
Net Debt to EBITDA-1.07
Interest Coverage Ratio20.92
Taxes
In the past 12 months, Marksans Pharma Limited has paid 1.40B in taxes.
Income Tax1.40B
Effective Tax Rate0.25
Enterprise Valuation
Marksans Pharma Limited EV to EBITDA ratio is 10.71, with an EV/FCF ratio of 18.42.
EV to Sales2.19
EV to EBITDA10.71
EV to Free Cash Flow18.42
EV to Operating Cash Flow13.42
Balance Sheet
Marksans Pharma Limited has ₹6.71B in cash and marketable securities with ₹3.32B in debt, giving a net cash position of ₹3.39B billion.
Cash & Marketable Securities₹6.71B
Total Debt₹3.32B
Net Cash₹3.39B
Net Cash Per Share₹7.49
Tangible Book Value Per Share₹63.78
Margins
Gross margin is 47.66%, with operating margin of 17.10%, and net profit margin of 14.16%.
Gross Margin47.66%
Operating Margin17.10%
Pretax Margin19.00%
Net Profit Margin14.16%
EBITDA Margin20.45%
EBIT Margin17.10%
Analyst Forecast
The average price target for Marksans Pharma Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast12.51%
EPS Growth Forecast9.82%